Navigation Links
AlphaDetail AlphaPulse™: Anticipated Impact of CATT Trial in Wet AMD Treatment

SAN MATEO, Calif., May 16, 2011 /PRNewswire/ -- On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing "Comparisons of Age-Related Macular Degeneration Treatments Trials" (CATT).

AlphaDetail, Inc., a leader in global ophthalmology primary market research and influence network mapping, has conducted its latest AlphaPulse survey with 120 Ophthalmologists to gauge their reactions on the heels of this important news.

Amy Tsang, a Director at AlphaDetail, explained, "The use of Avastin vs. Lucentis in Wet AMD has been debated among eye care professionals for years, and many anticipated that these results could bring closure to the issue."

While results from the trial confirmed that Avastin is non-inferior to Lucentis on visual acuity efficacy measures, the results related to level of risk associated with serious adverse events are less definitive.

  • 68% of surveyed Ophthalmologists are currently aware of the CATT trial results.
  • Perceived Benefits of Avastin
    • Over three-quarters of Ophthalmologists agree that the results from the CATT trial provide evidence that Avastin's cost savings outweigh its potential risks in Wet AMD.
    • Avastin is currently the dominant anti-VEGF therapy used to treat Wet AMD in the United States and this dominance is expected to continue among newly diagnosed patients in the future.
    • Based on the CATT trial results, Ophthalmologists intend to switch10-15% of their Wet AMD patients currently on Lucentis to Avastin over the next 6 months.

  • Perceived Benefits of Lucentis
    • Two-thirds of Ophthalmologists agree that Lucentis' superiority over Avastin in other efficacy-related attributes, such as lowering retinal thickness and decreasing retinal fluid, are important considerations when selecting the appropriate therapy for their patients.
    • Similarly, two-thirds of Ophthalmologists agree that data supporting equivalent long term efficacy between Lucentis and Avastin is still needed.
    • Finally, Ophthalmologists are divided on their level of concern about mortality rates and risk of hemorrhagic stroke with Avastin compared to Lucentis as shown in an analysis of 77,886 Wet AMD patients on Medicare.

To learn more about this study and to receive full results, please contact Amy Tsang at or (650) 581-3127.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us to answer our clients' most challenging questions.

SOURCE AlphaDetail, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
2. AlphaDetail Tracking Study Enhancements: The Advantage of Integration and Speed
3. AlphaDetail, Inc. Enhances Methodology / Advanced Analytics Capabilities
4. AlphaDetail Revenue Soars 30% in 2010
5. AlphaDetail Commemorates 10-Year Anniversary by Community Volunteering
6. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
7. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
8. New Mexico Software Enhances Technology Staff to Support Anticipated Sales Growth
9. TIGR® Matrix Surgical Mesh - Exhibited Ahead of Anticipated CE Mark Approval at European Hernia Society 2011, Ghent, Belgium
10. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
11. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Post Your Comments:
(Date:12/1/2015)... 2015 ... "Medium Molecular Weight Polyisobutylene Market for ... Applications - Global Industry Analysis, Size, Share, ... report to their offering. --> ... of the "Medium Molecular Weight Polyisobutylene ...
(Date:12/1/2015)... -- Royal Philips  (NYSE: PHG, AEX: PHIA) ... that produces high-contrast images for all anatomies in situations ... the 2015 Radiological Society of North America Annual ... digital imaging solution providing grid-like contrast improvement and enhanced ... supports "first-time-right imaging" by decreasing the need for retakes ...
(Date:12/1/2015)... WASHINGTON , Dec. 1, 2015  Athletic ... its founder have agreed to pay $1.35 million ... deceptively advertised the company,s copper-infused compression clothing would ... by arthritis and other diseases. ... also requires the company and its founder and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Physicians’ Education Resource®, LLC (PER®) ... announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will be held ... treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with powerful new ...
(Date:12/1/2015)... ... December 01, 2015 , ... Speech and ... believe that with innovative technologies and under the right circumstances, these practices can ... benefit of a dual-approach to his or her therapeutic sessions, as well as ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... the 7th Annual 2015 Golden Bridge Business Awards under the New Products and ... zero capex web based sample management software that helps labs organize ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. ... that the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior ... award celebrates exceptional special needs providers that excel in synthesizing the areas of ...
Breaking Medicine News(10 mins):